taken from the essential drug list and the database of drugs prices. Standard of treatment of CP developed by Ministry of Health of the Russian Federation was used for calculation of medical care costs. Costs of adverse events were calculated basing on Russian clinical guidelines and database of drugs prices. Disability pensions and disable child care were taken from the Russian Pension Fund database. The cost of orthopedic surgeries was calculated on the basis of RF Government program of state guarantees of free rendering to citizens of medical care. Results: Usage of AbobotulinumtoxinA treatment+standard therapy in whole population of SCP patients in Russia will result in 79,585 RUB/1,473 $ economy compared with OnabotulinumtoxinA+standard therapy, 131,178 RUB/2,429 $ economy compared with standard therapy per one patient for 2 years. This cost reduction is mainly attributed to decrease of number of orthopedic surgeries to the better efficacy of this BTA drug. ConClusions: Inclusion of abobotulinumtoxinA+standard therapy appears to be a cost saving treatment option in the management of spastic cerebral palsy in the Russian Federation compared with onabotulinumtoxinA+standard therapy and standard therapy solely.
objeCtives: PEGIFN beta-1a is the first pegylated interferon beta-1a administered subcutaneously every two weeks, indicated for the therapy of relapsing remitting multiple sclerosis (RRMS). The objective of this analysis was to estimate the potential economic impact following due of the introduction of PEGIFN beta-1a in Italy. Methods: The analysis was conducted with a three-year time horizon with the support of a decision-analytic model adopting the perspective of the Italian National Healthcare Service (NHS). Healthcare costs sustained by the Italian NHS for the management of the RRMS population (drug treatment, monitoring, relapse management, adverse event management) were calculated over 3 years and compared for two scenarios: i) The current scenario where only interferon beta and glatiramer acetate are RRMS patients available and ii) An alternative scenario after the introduction of PEGIFN beta-1a. The RRMS population was estimated to be approximately 35,500, 37,500 and 39,500 patients at Year 1, 2 and 3 respectively, based on published epidemiology literature and market data. The efficacy of treatments was simulated as reduction of relapse rates and was derived from a mixed treatment comparison. Unit costs were based on Italian 2015 prices and tariffs, and the published literature. A one-way sensitivity analysis was developed. Results: According to current price and reimbursement conditions established by the Italian NHS, the introduction of PEGIFNb-1a will result in cost savings. This model found that PEGIFN beta-1a would provide in related of treating RRMS patients an estimated annual costs of € 318,800,000, € 336,100,000 and € 353,600,000 in Year 1, 2, and 3 respectively compared to the costs of the current scenario of € 319,200,000, € 337,200,00 and € 355,200,000 in Year 1, 2, and 3, respectively. The cumulative budget reduction over the three year period was € 3,100,000 (an approximate 0.3% savings). ConClusions: The adoption of PEGIFN beta-1a for the treatment of RRMS is economically sustainable by the Italian NHS. bACkgRound: Epileptic seizures are associated with significantly impaired quality life, excessive healthcare resource use and thus high costs. According to published sources based on clinical data new anti-epileptic add-on therapy options for refractory patients with partial-onset seizures with or without secondary generalisation, such as lacosamide and perampanel, has achieved greater efficacy by responder rates (better control of the seizures) and seizure freedom than placebo being equally effective between each other. objeCtives: to estimate the budgetary impact of the introduction of 2 types of adjunctive treatment in adult patients with refractory partial epilepsy (RPE) -lacosamide and perampanel added to standard treatment, and to forecast this impact over the following three years in Kaliningrad region of Russian Federation. Methods: The budget impact model has been developed for the Russian Federation regions. Efficacy data used to assess the resource consumption was taken from randomized clinical trials and meta-analysis. The demographic parameters and the partial epilepsy incidence were calculated based on the official statistic surveillance system data for the regions. Resource use was estimated by expert survey. Drug and other medical costs were calculated on the basis of registered vital and essential drug list prices and regional tariffs. Results: Introduction of lacosamide to clinical practice (as add-on anti-epileptic treatment) compared to perampanel with equal market shares of 10%, 20% and 30% leads to average budget savings of healthcare system in Kaliningrad region, which amounted to: € 27 081.25 in first year, € 43 746.63 in the second year, € 78 119.00 in the third year, for treating 131, 140 and 149 patients with RPE, respectively. ConClusions: The analysis showed that introduction of adjunctive therapy with lacosamide in the market for the treatment of patients with PRE compared to perampanel could save budget funds by reducing drug costs in Russian Federation regions. SC IFNβ -1a is projected to avoid 28, 10, and 10 additional escalations to second-line therapy compared with IM IFNβ -1a, IFNβ -1b, and GA, respectively, resulting in cost savings of £685,391, £231,021, and £231,021. Results were most sensitive to each therapy's risk of relapse at 2 years. ConClusions: Among newly-diagnosed RRMS patients, treatment with SC IFNβ -1a is projected to avoid more relapses and escalations to second-line therapy compared with IM IFNβ -1a, IFNβ -1b, and GA over 2 years. These projected cost offsets within the UK may be applicable to other payer environments. toxIN a aND oNaBotulINum toxIN a for objeCtives: Botulinum toxins (BT) are a valuable treatment option for patients with post-stroke upper-limb spasticity (PS-ULS), which affects 33,000 patients in the UK. Xeomin (incobotulinum toxin A) and Botox (onabotulinum toxin A) are two BTs licensed for the treatment of PS-ULS. The treatment costs for Xeomin and Botox will depend on their real-world usage. Methods: Dosing data were collected for patients switching from Botox to Xeomin treatment between 2007-2012 from the Mid-Yorkshire Hospitals Trust (MYHT) UK (comprised of 3 centres). The dose of each BT received per limb at each visit was extracted from the dataset for 7 visits (the 3 visits before and 4 visits after switching). List prices from the British National Formulary for different vial sizes were applied to these data to generate a simple budget impact model. Results: 89 patients (127 limbs) were identified who switched treatment from Botox to Xeomin, of which 49 patients (54 limbs) fulfilled study criteria. The average dose of Xeomin was 147.2 units per limb and Botox was 156.9 units per limb. Due to the lower list price of Xeomin and the comparable dosing frequency between Botox and Xeomin (average time between injections was 154 days for Botox and 156 days for Xeomin), switching resulted in an average cost-saving of £26 per limb, per visit. This represented an estimated overall annual saving of £3,263. Accounting for sharing of vials reduced the estimated saving slightly (£3,166 overall). The real-world saving made by MYHT was greater than this as this analysis included upper-limb spasticity only, therefore a number of limbs did not fit study criteria and were not included in the estimated annual savings. ConClusions: Real-world dosing for Xeomin and Botox was comparable. Based on the lower list price of Xeomin, this indicated potential cost savings for switching from Botox to Xeomin. objeCtives: To compare direct medical costs for patients with relapsing-remitting multiple sclerosis (RRMS) treated with subcutaneous (sc) IFNβ 1a 44mcg three times weekly (TIW) versus other interferon-beta (IFNβ ) therapies across endpoints comprising the "no evidence of disease activity" (NEDA) measure. Methods: A decision-analytic model was developed using comparative efficacy data sourced from a network meta-analysis (NMA) of IFNβ therapies: scIFNβ 1a 44mcg TIW, scIFNβ 1b 250mcg every other day, intramuscular (im) IFNβ 1a 30mcg once weekly, and pegylated (peg) IFNβ 1a 125mcg every two weeks. The number of patients experiencing NEDA-related endpoints (relapse, new MRI activity, or disability progression) for each therapy was determined using risk ratios derived from odds ratios (ORs) vs. placebo (pairwise analysis) or vs. other IFNβ therapies (NMA analysis). The model followed 1,000 patients with RRMS over 2 years. Costs were sourced from the literature. One-way sensitivity analyses (OWSAs) were performed to test the robustness of the results. Results: Only medical costs were assessed, thus observed costoffsets meant fewer patients experienced NEDA-related endpoints. For scIFNβ 1a 44mcg vs. pegIFNβ 1a, results from the pairwise analysis projected cost-offsets of $893,652 (relapse) and $252,219 (MRI); results from the NMA also projected costoffsets of $578,174 (relapse), $15,628 (disability), and $105,667 (MRI). For scIFNβ 1a 44mcg vs. imIFNβ 1a, results from the pairwise analysis projected cost-offsets of $755,737 (relapse) and $239,926 (MRI); results from the NMA also projected costoffsets of $525,511 (relapse), $118,716 (disability), and $110,435 (MRI). For scIFNβ 1a 44mcg vs. scIFNβ 1b, results from the pairwise analysis projected cost-offsets of $84,826 (relapse) and $32,435 (disability); results from the NMA also projected a cost-offset of $35,948 (disability). OWSAs confirmed substantial cost-offsets for the comparisons examined. ConClusions: The results of this decision-analytic model suggests that scIFNβ 1a 44mcg provides substantial cost-offsets versus other IFNβ treatments across NEDA-related endpoints. To conduct budget impact analysis of abobotulinumtoxinA+standard therapy, onabotulinumtoxinA+standard therapy and standard therapy solely in patients with spastic cerebral palsy (SCP) in Russia for 2-year period. Total number of patients with spastic cerebral palsy in Russia is 55 899. Methods: A budget impact model was developed in Excel 2013 to simulate the costs of spastic cerebral palsy therapy in the Russian Federation. The following costs were taken into account: the costs of pharmacotherapy, inpatient and outpatient, sanatorium-resort care, costs of adverse events, casting, orthopedic surgeons, disability pensions, disable child care benefit. Costs of pharmacotherapy were
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